Global Health News Brief: Restructuring and Strategic Moves

A summary of recent health-related developments, covering topics such as Surgery Partners rejecting Bain Capital's offer, U.S. pharmaceuticals focusing on China for drug deals, Purdue Pharma securing support for a $7.4 billion opioid settlement, and Kraft Heinz's commitment to eliminating artificial colors by 2027.

In recent health sector developments, Surgery Partners has announced its rejection of Bain Capital's take-private proposal due to disagreements over terms, leading to a 13% drop in share value.

Meanwhile, U.S. pharmaceutical companies are increasingly turning to Chinese companies for licensing deals, aiming to transform them into lucrative treatments, with 14 deals amounting to $18.3 billion signed so far this year.

Additionally, Purdue Pharma's proposed $7.4 billion settlement, addressing numerous opioid lawsuits, has garnered substantial support from state attorneys general, potentially facilitating court approval for bankruptcy reorganization.

(With inputs from agencies.)